Skip to main content
$16.47 $0.08 (0.5%)

04:00 PM EST on 12/01/20

Nektar Therapeutics (NASDAQ:NKTR)

CAPS Rating: 3 out of 5

A biopharmaceutical company which develops breakthrough products that make a difference in patients' lives. It creates differentiated, innovative products by applying its platform technologies to established or novel medicines.

Current Price $16.47 Mkt Cap $2.9B
Open $16.39 P/E Ratio 0.00
Prev. Close $16.39 Div. (Yield) $0.00 (0.0%)
Daily Range $16.16 - $16.64 Volume 1,093,983
52-Wk Range $13.63 - $28.60 Avg. Daily Vol. 1,015,912

Caps

How do you think NASDAQ:NKTR will perform against the market?

Add Stock to CAPS Watchlist

All Players

253 Outperform
37 Underperform
 

All-Star Players

46 Outperform
8 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:NKTR Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

TMFEBCapital (96.96)
Submitted April 26, 2017

Mgmt is seeking a commercialization partner for its chronic back pain drug following late-stage success. The drug targets mu-opioid receptors, but it's more selective, and passes the blood brain barrier less easily, so its less prone to abuse. I… More

MarkBiotech (< 20)
Submitted January 25, 2018

many alternatives to opiods for pain which doesn't include 181. results for stand alone opdivo, keytruda for cancer melanoma, RCC are already robust. minimal benefit for 214 combo, or even arguably, no CLEAR benefit with the addition of 214. also,… More

NASDAQ:NKTR VS S&P 500 (SPY)

Fools bullish on NASDAQ:NKTR are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about NKTR.

Recs

0
Member Avatar TMFBiologyFool (63.89) Submitted: 9/4/2019 12:38:42 PM : Outperform Start Price: $17.04 NASDAQ:NKTR Score: -28.07

Punished too much for manufacturing issues.

Recs

0
Member Avatar TMFBigFrog (81.05) Submitted: 12/26/2018 8:40:05 AM : Outperform Start Price: $30.77 NASDAQ:NKTR Score: -101.51

Reasonable pipeline despite near term uncertainty.

Recs

0
Member Avatar healthcarevalue (68.96) Submitted: 11/26/2018 5:37:33 PM : Outperform Start Price: $38.63 NASDAQ:NKTR Score: -94.72

Return on invested capital of over 64 in twelve trailing months. Price earnings ratio of 9 is pretty low and reasonable price. Debt equity ratio of 0.14 from latest quarter shows financial health is good. Market capitalization of 6.749 billion, combined with the high return on invested capital and low debt and low price earnings ratio, shows a healthy potential for acquisition, perhaps by another biotechnology firm, in order to expand their offerings and research.

Leaderboard

Find the members with the highest scoring picks in NKTR.

Score Leader

kensigton

kensigton (91.17) Score: +225.33

The Score Leader is the player with the highest score across all their picks in NKTR.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
shorttest4 31.24 3/8/2010 Underperform 5Y $15.07 +9.29% +220.18% +210.89 0 Comment
anticishort 33.07 3/30/2010 Underperform 5Y $15.39 +7.02% +211.46% +204.44 0 Comment
rds11093 79.68 11/17/2006 Underperform 1Y $16.13 +2.11% +177.63% +175.52 0 Comment
dfktaxman < 20 12/13/2006 Underperform 1Y $16.70 -1.38% +173.15% +174.53 1 Comment
LMow 50.21 12/19/2006 Underperform NS $15.99 +3.00% +174.70% +171.70 0 Comment
tkaskmaster 54.74 6/23/2008 Outperform 1Y $3.60 +357.50% +187.43% +170.07 0 Comment
lanceur 97.34 5/21/2009 Underperform 5Y $6.62 +148.79% +313.41% +164.62 0 Comment
bone777 < 20 7/10/2008 Outperform 3Y $3.60 +357.50% +204.31% +153.19 0 Comment
anticitrademix2 < 20 11/2/2009 Underperform 5Y $8.15 +102.09% +251.33% +149.24 0 Comment
anticitrademix < 20 11/2/2009 Underperform 5Y $8.15 +102.09% +251.33% +149.24 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for NKTR.